These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37949730)

  • 1. Long-term Outcomes from a Phase 1 Dose Escalation Study Using Stereotactic Body Radiotherapy for Patients with Low- or Intermediate-risk Prostate Cancer.
    Moore A; Kollmeier MA; McBride SM; Toumbacaris N; Zhang Z; Lacy-Elsayegh A; Dreyfuss A; Grossman CE; Gorovets D; Zelefsky MJ
    Eur Urol Oncol; 2024 Aug; 7(4):812-820. PubMed ID: 37949730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer.
    Zelefsky MJ; Pinitpatcharalert A; Kollmeier M; Goldman DA; McBride S; Gorovets D; Zhang Z; Varghese M; Happersett L; Tyagi N; Hunt M
    Eur Urol Oncol; 2020 Dec; 3(6):748-755. PubMed ID: 31668713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.
    Zelefsky MJ; Kollmeier M; McBride S; Varghese M; Mychalczak B; Gewanter R; Garg MK; Happersett L; Goldman DA; Pei I; Lin M; Zhang Z; Cox BW
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):42-49. PubMed ID: 30611838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
    Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot Study.
    Parsai S; Juloori A; Sedor G; Reddy CA; Thousand R; Magnelli A; Berglund RK; Stovsky M; Klein EA; Tendulkar RD; Stephans KL
    Am J Clin Oncol; 2020 Jul; 43(7):469-476. PubMed ID: 32349020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial.
    Yasar B; Suh YE; Chapman E; Nicholls L; Henderson D; Jones C; Morrison K; Wells E; Henderson J; Meehan C; Sohaib A; Taylor H; Tree A; van As N
    Int J Radiat Oncol Biol Phys; 2024 Sep; 120(1):49-58. PubMed ID: 38499253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity.
    Franzese C; Badalamenti M; Di Brina L; D'Agostino G; Franceschini D; Comito T; Clerici E; Navarria P; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
    Strahlenther Onkol; 2020 Jul; 196(7):608-616. PubMed ID: 32303782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase 1 Trial for Patients With Low- and Intermediate-Risk Prostate Cancer.
    Potters L; Rana Z; Lee L; Cox BW
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):334-342. PubMed ID: 30721721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased toxicities associated with dose escalation of stereotactic body radiation therapy in prostate cancer: results from a phase I/II study.
    Hirata T; Suzuki O; Otani K; Miyake A; Tamari K; Seo Y; Isohashi F; Kai N; Hatano K; Fujita K; Uemura M; Imamura R; Tamenaga S; Yoshino Y; Fumimoto Y; Yoshioka Y; Nonomura N; Ogawa K
    Acta Oncol; 2023 May; 62(5):488-494. PubMed ID: 37203203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic Body Radiation Therapy to the Prostate Bed: Results of a Phase 1 Dose-Escalation Trial.
    Sampath S; Frankel P; Vecchio BD; Ruel N; Yuh B; Liu A; Tsai T; Wong J
    Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):537-545. PubMed ID: 31733323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
    Herrera FG; Valerio M; Berthold D; Tawadros T; Meuwly JY; Vallet V; Baumgartner P; Thierry AC; De Bari B; Jichlinski P; Kandalaft L; Coukos G; Harari A; Bourhis J
    Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):320-334. PubMed ID: 30267761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes.
    Fuller DB; Falchook AD; Crabtree T; Kane BL; Medbery CA; Underhill K; Gray JR; Peddada A; Chen RC
    Eur Urol Oncol; 2018 Dec; 1(6):540-547. PubMed ID: 31158102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial.
    Greco C; Pares O; Pimentel N; Louro V; Santiago I; Vieira S; Stroom J; Mateus D; Soares A; Marques J; Freitas E; Coelho G; Seixas M; Lopez-Beltran A; Fuks Z
    JAMA Oncol; 2021 May; 7(5):700-708. PubMed ID: 33704378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes of Prostate SBRT Using Non-adaptive MR-Guided Radiotherapy.
    Sandoval ML; Rishi A; Latifi K; Grass GD; Torres-Roca J; Rosenberg SA; Yamoah K; Johnstone PAS
    Cancer Control; 2024; 31():10732748241270595. PubMed ID: 39206515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.
    Spratt DE; Zumsteg ZS; Ghadjar P; Kollmeier MA; Pei X; Cohen G; Polkinghorn W; Yamada Y; Zelefsky MJ
    BJU Int; 2014 Sep; 114(3):360-7. PubMed ID: 24447404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.
    Meier RM; Bloch DA; Cotrutz C; Beckman AC; Henning GT; Woodhouse SA; Williamson SK; Mohideen N; Dombrowski JJ; Hong RL; Brachman DG; Linson PW; Kaplan ID
    Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):296-303. PubMed ID: 30191864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer.
    Alongi F; Mazzola R; Fiorentino A; Corradini S; Aiello D; Figlia V; Gregucci F; Ballario R; Cavalleri S; Ruggieri R
    Strahlenther Onkol; 2019 Feb; 195(2):113-120. PubMed ID: 30003292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial.
    Ma TM; Ballas LK; Wilhalme H; Sachdeva A; Chong N; Sharma S; Yang T; Basehart V; Reiter RE; Saigal C; Chamie K; Litwin MS; Rettig MB; Nickols NG; Yoon SM; Smith L; Gao Y; Steinberg ML; Cao M; Kishan AU
    Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):142-152. PubMed ID: 36007724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients.
    Pontoriero A; Iatì G; Mondello S; Midili F; Siragusa C; Brogna A; Ielo I; Anastasi G; Magno C; Pergolizzi S; De Renzis C
    Technol Cancer Res Treat; 2016 Feb; 15(1):179-85. PubMed ID: 25586517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
    Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
    Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.